Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1,518 JPY | -0.10% | +1.03% | -35.36% |
05/04 | Menicon Establishes German Subsidiary and Alters Capital Increase Payment Timing | MT |
04/04 | Menicon Buys French Specialty Contact Lens Maker Dencott | MT |
Strengths
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-35.36% | 735M | B- | ||
+11.01% | 98.12B | B | ||
-4.99% | 17.66B | B- | ||
-15.23% | 2.24B | D+ | ||
-11.56% | 1.54B | C+ | ||
+30.39% | 1.23B | - | ||
-34.40% | 747M | - | ||
-6.68% | 623M | - | ||
+27.68% | 494M | - | - | |
+19.35% | 493M | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 7780 Stock
- Ratings Menicon Co., Ltd.